Latest Clinical Trials
Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica Zhejiang University NA
COMPLETED
(Sep 1, 2026)
PHASE3 Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer Second Affiliated Hospital, Zhejiang University, School of Medicine NA
RECRUITING
(Sep 1, 2026)
PHASE2 The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery Zhejiang University NA
COMPLETED
(Aug 1, 2026)
PHASE2 Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study Zhejiang Cancer Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE2 VG081821AC Tablets for Early to Mid-stage Parkinson's Disease Zhejiang Vimgreen Pharmaceuticals, Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma Second Affiliated Hospital, Zhejiang University, School of Medicine NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Bridging Study of XKH001 in Healthy Adult Caucasian Participants Zhejiang Kanova Biopharmaceutical Co., LTD NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer Zhejiang University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Sintilimab Plus Hypofractionated Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma Second Affiliated Hospital, Zhejiang University, School of Medicine NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis Zhejiang Cancer Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer First Affiliated Hospital of Zhejiang University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Platinum-Free Regimen in Nasopharyngeal Carcinoma Zhejiang Cancer Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Bevacizumab in the Treatment of HHT Second Affiliated Hospital, Zhejiang University, School of Medicine NA
RECRUITING
(Aug 1, 2026)
PHASE2 Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Zhejiang Cancer Hospital NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer Second Affiliated Hospital, School of Medicine, Zhejiang University NA
RECRUITING
(Jul 1, 2026)
PHASE2 Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma Zhejiang Cancer Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer Zhejiang Cancer Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Elemene Liposomes in Endometrial Cancer Women's Hospital School Of Medicine Zhejiang University NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy Second Affiliated Hospital, Zhejiang University, School of Medicine NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 Zhejiang University NA
RECRUITING
(Jun 1, 2026)
PHASE3 Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study Second Affiliated Hospital, School of Medicine, Zhejiang University NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1 Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ First Affiliated Hospital of Zhejiang University NA
RECRUITING
(Jun 1, 2026)
PHASE1 A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia Zhejiang Doer Biologics Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases Zhejiang University NA
RECRUITING
(Jun 1, 2026)
PHASE2 CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. Zhejiang Cancer Hospital NA
RECRUITING
(May 1, 2026)
PHASE2 Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer Second Affiliated Hospital, School of Medicine, Zhejiang University NA
RECRUITING
(May 1, 2026)
PHASE2 Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer Second Affiliated Hospital, School of Medicine, Zhejiang University NA
RECRUITING
(May 1, 2026)
PHASE2 QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer Second Affiliated Hospital, School of Medicine, Zhejiang University NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer First Affiliated Hospital of Zhejiang University NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV First Affiliated Hospital of Zhejiang University NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy First Affiliated Hospital of Zhejiang University NA
ENROLLING BY INVITATION
(May 1, 2026)
PHASE2, PHASE3 Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy First Affiliated Hospital of Zhejiang University NA
ENROLLING BY INVITATION
(May 1, 2026)
PHASE2, PHASE3 CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma Zhejiang University NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors Zhejiang Anglikang Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis The Fourth Affiliated Hospital of Zhejiang University School of Medicine NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure Second Affiliated Hospital, School of Medicine, Zhejiang University NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor Zhejiang University NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study Zhejiang Cancer Hospital NA
COMPLETED
(Mar 1, 2026)
PHASE2 Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection Zhejiang Kanova Biopharmaceutical Co., LTD NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 
